- Conditions
- Prostate Cancer, Bone Metastases
- Interventions
- MCS110
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • San Antonio, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 2,338
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- liraglutide, placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 14
- States / cities
- Cypress, California • Los Angeles, California • Aurora, Colorado + 10 more
- Conditions
- Neoplasms
- Interventions
- GSK525762, Placebo, Fulvestrant
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Type 1 Diabetes
- Interventions
- Glucagon Nasal Powder [Baqsimi]
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 4 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- 500mcg/25mcg once daily, Placebo once daily
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 4
- States / cities
- Chester, South Carolina • Gaffney, South Carolina • Greenville, South Carolina + 1 more
- Conditions
- Solid Tumor
- Interventions
- PYX-106
- Drug
- Lead sponsor
- Pyxis Oncology, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Alzheimer Disease
- Interventions
- SAM-531, placebo
- Drug · Other
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 7
- States / cities
- Delray Beach, Florida • Hallandale, Florida • St. Petersburg, Florida + 4 more
- Conditions
- Erosive Esophagitis
- Interventions
- H008, H008 placebo, Lansoprazole
- Drug
- Lead sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- GTI-2040, gemcitabine hydrochloride, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Parkinson Disease
- Interventions
- Opicapone, Carbidopa Levodopa
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Glendale, California • Long Beach, California • Farmington Hills, Michigan
- Conditions
- Solid Tumors
- Interventions
- ALN-VSP02
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more
- Conditions
- HIV
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Relapsed/Refractory B-cell Malignancies
- Interventions
- UBX-303061
- Drug
- Lead sponsor
- Ubix Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Canton, Oklahoma • Houston, Texas
- Conditions
- Parkinson's Disease
- Interventions
- venglustat GZ/SAR402671, Placebo
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • La Jolla, California • Palo Alto, California + 10 more
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck, Renal Cell Carcinoma
- Interventions
- etakafusp alfa (AB248), pembrolizumab
- Biological
- Lead sponsor
- Asher Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 20
- States / cities
- Duarte, California • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Macular Degeneration
- Interventions
- RO6867461
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 5
- States / cities
- Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
- Conditions
- End Stage Renal Disease
- Interventions
- Ertapenem
- Drug
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Dearborn, Michigan
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia
- Interventions
- Pociredir oral capsule(s)
- Drug
- Lead sponsor
- Fulcrum Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 11 more
- Conditions
- Healthy
- Interventions
- Galcanezumab
- Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
- Conditions
- Advanced Malignancies
- Interventions
- Patupilone
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- End-Stage Renal Disease
- Interventions
- Rivaroxaban 15 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Healthy Volunteer
- Interventions
- RO6811135, placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Baton Rouge, Louisiana • New Orleans, Louisiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- ATI-450, Placebo oral tablet
- Drug
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 17 more